This company listing is no longer active
TCR2 Therapeutics Past Earnings Performance
Past criteria checks 0/6
TCR2 Therapeutics's earnings have been declining at an average annual rate of -16%, while the Biotechs industry saw earnings growing at 10.8% annually.
Key information
-16.0%
Earnings growth rate
87.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -161.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
This section of the company report contains some beta features.
Revenue & Expenses BreakdownBeta
How TCR2 Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -163 | 41 | 91 |
| 31 Dec 22 | 0 | -152 | 39 | 84 |
| 30 Sep 22 | 0 | -119 | 38 | 77 |
| 30 Jun 22 | 0 | -115 | 39 | 72 |
| 31 Mar 22 | 0 | -107 | 39 | 65 |
| 31 Dec 21 | 0 | -100 | 37 | 59 |
| 30 Sep 21 | 0 | -91 | 34 | 57 |
| 30 Jun 21 | 0 | -81 | 32 | 50 |
| 31 Mar 21 | 0 | -73 | 25 | 49 |
| 31 Dec 20 | 0 | -67 | 22 | 46 |
| 30 Sep 20 | 0 | -61 | 22 | 42 |
| 30 Jun 20 | 0 | -58 | 18 | 43 |
| 31 Mar 20 | 0 | -53 | 20 | 37 |
| 31 Dec 19 | 0 | -97 | 18 | 33 |
| 30 Sep 19 | 0 | -96 | 16 | 31 |
| 30 Jun 19 | 0 | -100 | 13 | 25 |
| 31 Mar 19 | 0 | -107 | 11 | 22 |
| 31 Dec 18 | 0 | -62 | 9 | 17 |
| 30 Sep 18 | 0 | -55 | 9 | 13 |
| 31 Dec 17 | 0 | -15 | 5 | 8 |
Quality Earnings: 2K7 is currently unprofitable.
Growing Profit Margin: 2K7 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2K7 is unprofitable, and losses have increased over the past 5 years at a rate of 16% per year.
Accelerating Growth: Unable to compare 2K7's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2K7 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12%).
Return on Equity
High ROE: 2K7 has a negative Return on Equity (-160.96%), as it is currently unprofitable.